Herpesvirus type 6 in patients undergoing bone marrow transplantation: serologic features and detection by polymerase chain reaction.
Herpesvirus type 6 in patients undergoing bone marrow transplantation: serologic features and detection by polymerase chain reaction.
复制标题
接受骨髓移植的患者中的 6 型疱疹病毒：血清学特征和聚合酶链反应检测。
DOI：
10.1182/blood.v83.10.3052.3052
复制
发表时间：
1994
期刊：
影响因子：
20.3
通讯作者：
W. Siegert
中科院分区：
文献类型：
--
作者：
F. Wilborn;Volker Brinkmann;Volker Brinkmann;C. A. Schmidt;C. A. Schmidt;Frank Neipel;Frank Neipel;Hans Gelderblom;Hans Gelderblom;W. Siegert;W. Siegert
为探讨人类疱疹病毒6型(HHV-6)感染在骨髓移植(BMT)患者中的潜在作用，采用聚合酶链式反应(PCR)对57例BMT患者骨髓移植前后患者外周血白细胞、口腔灌洗液和尿液中HHV-6DNA进行了检测。24例接受自体骨髓移植的患者和36例接受同种异体骨髓移植的患者进行了研究。36名患者(60%)在一次或多次检测中呈阳性。大多数PCR阳性患者仅在1周(n=23)或2周(n=5)内偶见阳性结果。6例在3~5周内呈阳性反应。在2名患者中，我们发现阳性试验的频率很高，分析了7周中的7周和10周中的10周。24名患者(40%)在整个骨髓移植后期间一直保持PCR阴性。HHV-6聚合酶链式反应结果与急性移植物抗宿主病(AGVHD)的发生有显著相关性。在II-IV级中，8名患者中有6名(75%)有2项或2项以上的聚合酶链式反应阳性，而25名无或有I级aGVHD的患者中有5名(20%)(P=0.01)。在骨髓移植类型或骨髓移植前HHV-6酶联免疫吸附试验滴度方面，聚合酶链式反应检测结果没有差异。对18例患者进行限制性内切酶分析，发现HHV-6B变种16例(88.9%)，变种A 2例(11.1%)。我们的结论是，骨髓移植后60%的患者可以检测到HHV-6DNA。中、重度aGVHD患者HHV-6DNA的检出频率高于非aGVHD患者或轻度aGVHD患者。
To evaluate the potential role of human herpesvirus type 6 (HHV-6) infection in patients after bone marrow transplantation (BMT) we sequentially analyzed buffy coat leukocytes, oral lavage fluid, and urine from 57 patients for the presence of HHV-6 DNA by polymerase chain reaction (PCR) before and after 60 BMTs. Twenty-four patients undergoing autologous BMT and 36 with allogeneic BMT were studied. Thirty-six patients (60%) were PCR positive in one or more tests. The majority of PCR-positive patients had positive results only sporadically, in 1 (n = 23) or 2 weeks (n = 5). Six patients were positive in 3 to 5 weeks. In 2 patients, we found a high frequency of positive tests, in 7 of 7 and 10 of 10 weeks analyzed. Twenty-four patients (40%) remained PCR negative throughout the post-BMT period. There was a significant correlation between the results of HHV-6 PCR and the occurrence of acute graft-versus-host disease (aGVHD). In grade II-IV, 6 of 8 (75%) patients had 2 or more positive PCR tests, compared with 5 of 25 (20%) patients without or with grade I aGVHD (P = .01). There was no difference in the outcome of PCR tests with respect to the type of BMT or pre-BMT HHV-6 enzyme-linked immunosorbent assay titers. Restriction enzyme analysis of PCR amplificates from 18 patients showed HHV-6 variant B in 16 (88.9%) and variant A in 2 cases (11.1%). We conclude that HHV-6 DNA can be detected in 60% of the patients after BMT. HHV-6 DNA can be detected more frequently in patients with moderate and severe aGVHD than in patients without aGVHD or with mild aGVHD.